Indoco Remedies launches FEVINDO : 400 mg Favipiravir


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ indoco-remedies-launches-favipiravir-fevindo-400-mg
Now Indoco joins Favipiravir production with 400mg tablets

(Favipiravir) 400 mg Tablets in India. Fevindo - 400 (Favipiravir) is an antiviral drug, effective against the RNA-based influenza virus. The drug has been approved by DCGI in the treatment of Covid-19. Fevindo 400 reduces pill burden by 50% and ensures convenient dosing and better patient compliance.

Ms. Aditi Kare Panandikar, Managing Director - Indoco Remedies Ltd. commented, “The Covid-19 crisis has created a vast disruption to life in India and all over the globe. As part of the pharma industry, we have been able to do our bit in the prevention of Covid-19 with our brands Karvol Plus, ATM, Febrex Plus and Rexidin SRS Mouthwash. With the launch of FEVINDO, we are taking the next step from prevention to the treatment of Covid-19.”

Fevindo - 400 (Favipiravir) will be made available at all government approved COVID care centres and selected medical practitioners across the country. In addition to Fevindo, Indoco has two more new products for launch in Covid Care range, i.e., Povidone Iodine Gargle and Immunity booster chewable tablets with Zinc, Vitamin C and Vitamin D. Indoco has always been committed to providing quality medicines at affordable prices and with the launch of these products, the Company is all set to venture into the treatment of Covid-19.

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma company with presence in 55 countries. Indoco, a USD 145 million Company, employs over 5500 people including more than 300 skilled scientists. The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from over 3,00,000 doctors belonging to various specialities.

Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal,

Tags : #IndocoRemedies #FavipiravirLaunch #IndocoFavipiravir #FevindoFavipiravir #latestFavipiravirNewsSep28 #latestPharmaNewsSep28

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Vahan.ai Advances Multilingual AI Recruitment with NVIDIA NemotronAugust 25, 2026
Vahan.ai Advances Multilingual AI Recruitment with NVIDIA NemotronAugust 25, 2026
Beyond Basic Baby Care: Addressing the Monsoon Surge in Infant Skin Concerns with Salve’s Littloo RangeAugust 25, 2026
100+ Bengaluru Clinics Use QR678® as Indian Hair Regeneration Platform Adds New Patent and Expands GloballyAugust 25, 2026
Healthcare Innovation in India: Real Stories That Are Reshaping the Future of MedicineAugust 25, 2026
Generative AI in Indian Hospitals: Where It Is Actually Making a Difference in 2026August 25, 2026
High Uric Acid and Gout: Symptoms, Causes, Diet, Tests, and Treatment ExplainedAugust 24, 2026
Vitamin D Deficiency in India: Symptoms, Causes, Tests, Treatment and PreventionAugust 24, 2026
SRM College of Pharmacy Hosts Two-Day National Pharmaceutical ConferenceAugust 21, 2026
Atomy India Joins Hands with the Paralympic Committee of India as OfficialNutrition and Wellness PartnerAugust 21, 2026
Thumbay International Pathway - MD Program with Installments and a Direct Route to Residency in RomaniaAugust 21, 2026
THIP wins ‘Breakthrough Digital Patient Education Initiative’ award at India Vaccine Leaders Conclave in PuneAugust 21, 2026
Three Watermelons, a Mannequin Head and a PS5: What India Left Behind on Intercity BusesAugust 21, 2026
Evaluating Thyroid Nodules: Fine Needle Aspiration Cytology (FNAC) and Bethesda ClassificationAugust 21, 2026
Clinical Approaches to Acute Kidney Injury (AKI): Biomarkers, Staging, and Renal Replacement TherapyAugust 21, 2026
Diabetes Care in India: Understanding the Crisis, Bridging the Gaps, and Building a Healthier FutureAugust 21, 2026
Diabetes Management: Lifestyle Changes That Make a Real DifferenceAugust 21, 2026
TagMango introduces New AI capabilities for creator businesses at RISE 2026August 20, 2026
AFib: The Irregular Heartbeat We Need to Stop IgnoringAugust 20, 2026
Nanavati Max Launches Dedicated Cancer Helpline to Support Patients and Families In Their Cancer JourneyAugust 20, 2026